CSPC Pharmaceutical Group Ltd
Company Profile
Business description
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
Contact
No.896 Zhongshandong Street
Gaoxin District
Hebei Province
Shijiazhuang050035
CHNT: +86 31187037015
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
19,700
Stocks News & Analysis
stocks
The strange effect of the 30% minimum capital gains tax
stocks
Major ASX miner reduces aluminium exposure
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,000.50 | 43.00 | -0.48% |
| CAC 40 | 8,479.87 | 28.20 | -0.33% |
| DAX 40 | 25,817.89 | 38.58 | 0.15% |
| Dow JONES (US) | 53,055.91 | 155.84 | 0.29% |
| FTSE 100 | 10,651.77 | 27.26 | -0.26% |
| HKSE | 23,517.70 | 98.62 | -0.42% |
| NASDAQ | 26,121.16 | 288.49 | 1.12% |
| Nikkei 225 | 68,540.78 | 1,196.91 | -1.72% |
| NZX 50 Index | 13,769.55 | 6.45 | 0.05% |
| S&P 500 | 7,537.43 | 54.19 | 0.72% |
| S&P/ASX 200 | 8,797.10 | 42.30 | -0.48% |
| SSE Composite Index | 3,999.03 | 42.21 | -1.04% |